NCT06362122 Anatomo-clinico-biological Profiles in Severe Nasal Polyps
| NCT ID | NCT06362122 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Poitiers University Hospital |
| Condition | NASAL POLYPS |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-06-03 |
| Primary Completion | 2026-05-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2024-06-03 with a primary completion date of 2026-05-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Nasal sinus polyposis is a chronic inflammatory pathology of the nasal cavity and sinus cavities that causes bilateral and multifocal polyp development and has a prevalence of 2 to 4% in the general population. Therapeutic management consists of first-line medical treatment for anti-inflammatory purposes. Local corticosteroid therapy, using nasal sprays, is the background treatment. Surgical management is offered to patients in case of failure of medical treatment. Although effective, surgery does not protect patients from recurrence of symptoms related to regrowth of polyps. Recently, biologics have appeared, which despite its effectiveness, about 20% of patients have a partial or no response to these treatments. There is currently no possibility of determining the probability of response to treatments in patients. It is therefore essential to determine an anatomo-clinico-biological correlation associating the anatomopathological profile, the clinical characteristics and the cytokine signature in order to best guide the patient's management, including the initiation of biotherapy. Indeed, patients, according to their clinical, biological characteristics and the cytokine signature of their polyps will react differently to different treatments, including surgery and biotherapy. This correlation will serve as a predictor of treatment response.
Eligibility Criteria
Inclusion Criteria: * Patient ≥ 18 year-old * Patient with nasal sinus polyposis resistant to medical treatment and requiring surgical treatment with ethmoidectomy type is considered for the first time * Having signed the consent form * Having an health insurance Exclusion Criteria: * Current or past biotherapy treatment * Taking general corticosteroid therapy within 4 weeks of surgery * Protected person * Pregnant women or lactating women
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06362122 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying NASAL POLYPS. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06362122 currently recruiting?
Yes, NCT06362122 is actively recruiting participants. Contact the research team at Florent.CARSUZAA@chu-poitiers.fr for enrollment information.
Where is the NCT06362122 trial being conducted?
This trial is being conducted at Poitiers, France.
Who is sponsoring the NCT06362122 clinical trial?
NCT06362122 is sponsored by Poitiers University Hospital. The trial plans to enroll 200 participants.